Key clinical point: Treatment with apremilast in patients with moderate psoriatic arthritis disease activity at baseline is more likely to reach treatment targets by 52 weeks than its use in patients with high activity.
Major finding: Nearly twice as many psoriatic arthritis patients with moderate disease activity at baseline achieved treatment targets with apremilast, compared with those who started with high activity.
Study details: Analysis of data from 494 patients with psoriatic arthritis in the PALACE 1-3 studies.
Disclosures: The study was sponsored by Celgene. Three authors were employees of Celgene at the time of the study, and nine authors declared a range of consultancies, grants, research, and other support from the pharmaceutical sector, including from Celgene.
Mease P et al. Arthritis Care Res. 2019 Jan 7. doi: 10.1002/acr.24134.